Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Training the next generation of pharmacometric modelers: a multisector perspective.
Bonate PL, Barrett JS, Ait-Oudhia S, Brundage R, Corrigan B, Duffull S, Gastonguay M, Karlsson MO, Kijima S, Krause A, Lovern M, Riggs MM, Neely M, Ouellet D, Plan EL, Rao GG, Standing J, Wilkins J, Zhu H. Bonate PL, et al. Among authors: rao gg. J Pharmacokinet Pharmacodyn. 2024 Feb;51(1):5-31. doi: 10.1007/s10928-023-09878-4. Epub 2023 Aug 13. J Pharmacokinet Pharmacodyn. 2024. PMID: 37573528
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective.
Bonate PL, Barrett JS, Ait-Oudhia S, Brundage R, Corrigan B, Duffull S, Gastonguay M, Karlsson MO, Kijima S, Krause A, Lovern M, Riggs MM, Neely M, Ouellet D, Plan EL, Rao GG, Standing J, Wilkins J, Zhu H. Bonate PL, et al. Among authors: rao gg. J Pharmacokinet Pharmacodyn. 2024 Feb;51(1):89. doi: 10.1007/s10928-023-09885-5. J Pharmacokinet Pharmacodyn. 2024. PMID: 37670078 No abstract available.
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Roque DM, et al. Among authors: rao gg. Br J Cancer. 2024 Apr;130(6):1073. doi: 10.1038/s41416-024-02628-4. Br J Cancer. 2024. PMID: 38438590 Free PMC article. No abstract available.
Integrated Transcriptomic and Metabolomic Mapping Reveals the Mechanism of Action of Ceftazidime/Avibactam against Pan-Drug-Resistant Klebsiella pneumoniae.
Hussein M, Allobawi R, Zhao J, Yu H, Neville SL, Wilksch J, Wong LJM, Baker M, McDevitt CA, Rao GG, Li J, Velkov T. Hussein M, et al. Among authors: rao gg. ACS Infect Dis. 2023 Dec 8;9(12):2409-2422. doi: 10.1021/acsinfecdis.3c00264. Epub 2023 Oct 25. ACS Infect Dis. 2023. PMID: 37878861 Free PMC article.
Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations.
Yeshwante SB, Hanafin P, Miller BK, Rank L, Murcia S, Xander C, Annis A, Baxter VK, Anderson EJ, Jermain B, Konicki R, Schmalstig AA, Stewart I, Braunstein M, Hickey AJ, Rao GG. Yeshwante SB, et al. Among authors: rao gg. Mol Pharm. 2023 Sep 4;20(9):4491-4504. doi: 10.1021/acs.molpharmaceut.3c00199. Epub 2023 Aug 17. Mol Pharm. 2023. PMID: 37590399
Bifunctional antibiotic hybrids: A review of clinical candidates.
Koh AJJ, Thombare V, Hussein M, Rao GG, Li J, Velkov T. Koh AJJ, et al. Among authors: rao gg. Front Pharmacol. 2023 Jun 12;14:1158152. doi: 10.3389/fphar.2023.1158152. eCollection 2023. Front Pharmacol. 2023. PMID: 37397488 Free PMC article. Review.
A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
Hanafin PO, Kwa A, Zavascki AP, Sandri AM, Scheetz MH, Kubin CJ, Shah J, Cherng BPZ, Yin MT, Wang J, Wang L, Calfee DP, Bolon M, Pogue JM, Purcell AW, Nation RL, Li J, Kaye KS, Rao GG. Hanafin PO, et al. Among authors: rao gg. Clin Microbiol Infect. 2023 Sep;29(9):1174-1181. doi: 10.1016/j.cmi.2023.05.018. Epub 2023 May 20. Clin Microbiol Infect. 2023. PMID: 37217076
179 results